

# Wound closure following hip arthroplasty

<b>Submission date</b> 25/01/2010	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 05/02/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/03/2017	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Roland Ingram

**Contact details**  
Glasgow Royal Infirmary  
Orthopaedics Department  
GateHouse Building  
Castle Street  
Glasgow  
United Kingdom  
G4 0SF  
-  
Roland.Ingram@ggc.scot.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

# Study information

## Scientific Title

Wound closure following hip arthroplasty: a multicentre randomised controlled trial

## Study objectives

Closing wounds, after total hip replacement, with DERMABOND® (skin glue) in addition to sutures will significantly decrease wound leakage and consequently surgical site infection rates.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

West of Scotland Research Ethics Committee - pending approval as of 25/01/2010

## Study design

Multicentre three-armed randomised trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Post-operative wound leakage and surgical site infection

## Interventions

All subjects in each of three randomised groups will have total hip arthroplasty wounds closed in layers with absorbable sutures. Subcuticular skin closure will be performed using monofilament suture (3/0 Biosyn) to oppose the wound edges. Each group will differ in the method of wound dressing.

Group 1:

A standard absorbent dressing will be applied to the wound.

Group 2:

DERMABOND® tissue adhesive will be applied to the dry wound in multiple thin layers. The

width of the application will be approximately 5 mm either side of the incision. DERMABOND® will only be applied topically and never between wound edges. A standard absorbent dressing will be applied to the wound.

**Group 3:**

DERMABOND® tissue adhesive will be applied to the dry wound in multiple thin layers as for Group 2. A standard large Tegaderm™ dressing will then be applied to the wound.

The wound will be dressed for several weeks post-operatively but this will vary from patient to patient. Follow-up will be 3 months.

**Intervention Type**

Other

**Primary outcome measure**

Wound leakage at 3 days post-operative

**Secondary outcome measures**

1. Wound complications including infection, assessed daily until patient is discharged and followed up at 3 months, and discharge, assessed daily until patient is discharged from hospital. Any discharge beyond day 4 will be classified as prolonged
2. Time to discharge
3. Cosmetic appearance, measured using a modified Hollander Scale to assess cosmesis at 3 months post-operatively
4. Pain, measured using a visual analogue scale to assess pain daily until discharge and at 3 months

**Overall study start date**

05/04/2010

**Completion date**

01/04/2011

## **Eligibility**

**Key inclusion criteria**

1. Anyone requiring elective Total Hip Replacement at Glasgow Royal Infirmary or Royal Alexandra Hospital (Paisley)
2. Able to give informed consent
3. Aged over 18 years, either sex

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

219 in three groups

**Key exclusion criteria**

1. Known glue allergy
2. Coagulation disorder
3. Unable to give informed consent

**Date of first enrolment**

05/04/2010

**Date of final enrolment**

01/04/2011

**Locations****Countries of recruitment**

Scotland

United Kingdom

**Study participating centre**

Glasgow Royal Infirmary

Glasgow

United Kingdom

G4 0SF

**Sponsor information****Organisation**

NHS Greater Glasgow and Clyde (UK)

**Sponsor details**

R&D Management Office

Western Infirmary

38 Church Street

Glasgow

United Kingdom

G11 6NT

**Sponsor type**

Government

**Website**

<http://www.nhs.uk/content/>

**ROR**

<https://ror.org/05kdz4d87>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Glasgow Royal Infirmary (UK) - Orthopaedic Endowment Fund

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration